Protalix BioTherapeutics, Inc.
PLX
$2.79
-$0.0601-2.11%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.22M | 17.96M | 13.47M | 3.75M | 10.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.22M | 17.96M | 13.47M | 3.75M | 10.49M |
| Cost of Revenue | 3.89M | 8.38M | 9.46M | 2.60M | 8.86M |
| Gross Profit | 14.33M | 9.58M | 4.02M | 1.15M | 1.63M |
| SG&A Expenses | 3.00M | 2.60M | 3.48M | 3.12M | 4.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.01M | 13.97M | 15.90M | 8.60M | 16.10M |
| Operating Income | 7.21M | 3.99M | -2.43M | -4.86M | -5.62M |
| Income Before Tax | 7.32M | 3.84M | -2.27M | -4.73M | -6.43M |
| Income Tax Expenses | 822.00K | 607.00K | -69.00K | -138.00K | -382.00K |
| Earnings from Continuing Operations | 6.49M | 3.24M | -2.20M | -4.60M | -6.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.49M | 3.24M | -2.20M | -4.60M | -6.04M |
| EBIT | 7.21M | 3.99M | -2.43M | -4.86M | -5.62M |
| EBITDA | 7.54M | 4.32M | -2.11M | -4.53M | -5.30M |
| EPS Basic | 0.09 | 0.04 | -0.03 | -0.06 | -0.08 |
| Normalized Basic EPS | 0.07 | 0.03 | -0.02 | -0.04 | -0.06 |
| EPS Diluted | 0.06 | 0.03 | -0.03 | -0.06 | -0.08 |
| Normalized Diluted EPS | 0.04 | 0.03 | -0.02 | -0.04 | -0.06 |
| Average Basic Shares Outstanding | 70.22M | 73.55M | 73.31M | 73.04M | 72.62M |
| Average Diluted Shares Outstanding | 104.33M | 81.22M | 73.31M | 73.04M | 72.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |